Tag: inflammation

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s listing on the TSX

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License...

Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

AMI Pharm Advances AYP-101 to Phase 3, Redefining Fat-Reduction Injectable drug with Patient Comfort in Focus

SEOUL, South Korea, Aug. 11, 2025 /PRNewswire/ -- AMI Pharm, a biotechnology company focused on aesthetic and therapeutic innovations, announced today that its lead candidate,...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter,...

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 10, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™...

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™...

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™...

2025 Report: “PurDentix Reviews and Complaints” Surge Reflects Growing Curiosity Around Oral Microbiome Supplements

Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025

Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsInflammation

Synology showcases the next generation DiskStation Manager and a full lineup of data management solutions at COMPUTEX 2026

Bell Announces Upsizing and Results of its Cash Tender Offers for Debt Securities

LONGi Showcases LONGi ONE at SNEC 2026, Advancing Native Solar-Plus-Storage Integration

Tag: inflammation

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients

AMI Pharm Advances AYP-101 to Phase 3, Redefining Fat-Reduction Injectable drug with Patient Comfort in Focus

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

2025 Report: “PurDentix Reviews and Complaints” Surge Reflects Growing Curiosity Around Oral Microbiome Supplements

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us